Skip to main content
Download PDF

Volume 16 Supplement 3

Sepsis 2012

Evaluation of a soluble CD14 subtype in patients with surgical sepsis

Critical Care volume 16, Article number: P7 (2012) Cite this article

Background

Surgical sepsis remains a cause of poor outcome. In order to treat surgical sepsis appropriately, it is important to reach diagnosis of sepsis early during the course and start antibiotic treatment. The gold standard of sepsis diagnosis is blood culture but there are issues with its sensitivity along with contamination. Soluble CD14 subtype (sCD14st) is an N-terminal fragment of CD14, and signal messenger of lipopolysaccharide (LPS). sCD14st is reported to increase in sepsis patients. In this study, we evaluated the specificity, clinical effectiveness of soluble sCD14st in patients with surgical sepsis.

Methods

The study population was 18 operated patients in Kochi Health Sciences Center between April 2010 and March 2011. We investigated sCD14st using the compact automated enzyme immunoanalyzer PATHFAST (Mitsubishi Chemical Medience Co., Japan) and other biomarkers (procalcitonin (PCT), CRP, IL-6) at surgery (day 0) followed by 1, 3, 5, 7 days. APACHE II and Sequential Organ Failure Assessment (SOFA) were used to assess the sepsis severity. Sepsis was diagnosed according to the American College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) criteria.

Results

There were nine patients with acute abdomen, esophageal cancer in five patients, cerebral bleeding in two patients, and a patient with Fournier's gangrene and trauma, respectively. The area under the curves (AUC) of receiver operating characteristic (ROC) curve analysis for septic infection were 0.92 for sCD14st, 0.82 for PCT, 074 for IL-6, and 0.82 for CRP. Two esophageal cancer patients who indicated over 800pg/ml in sCD14st had complicated nosocomial pneumonia. sCD14st also positively correlated with SOFA sore (r = 0.41) and APACHE II score (r = 0.28).

Conclusion

sCD14st was a useful biomarker for the diagnosis of surgical sepsis and reflected clinical severity after operation.

Author information

Authors and Affiliations

  1. Kochi Health Sciences Center, Kochi, Japan

    Y Fukui

Authors
  1. Y Fukui
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Fukui, Y. Evaluation of a soluble CD14 subtype in patients with surgical sepsis. Crit Care 16 (Suppl 3), P7 (2012). https://doi.org/10.1186/cc11694

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/cc11694

Keywords

  • Esophageal Cancer
  • Sepsis Severity
  • Sequential Organ Failure Assessment
  • Procalcitonin
  • Cerebral Bleeding

Critical Care

ISSN: 1364-8535